Year All20242023202220212020201920182017201620152014 ABIVAX completes the second milestone in CaReNa, a “Strategic Industrial Innovation Project” supported by Bpifrance September 13, 2016 Read More Analysis of ongoing ABX203 Phase IIb/III trial in chronic hepatitis B virus infection shows good safety, but primary endpoint of study is unlikely to be reached June 17, 2016 Read More ABIVAX launches ABX464-004 study; First patient enrolled in second Phase IIa trial May 30, 2016 Read More ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa April 27, 2016 Read More ABIVAX enters into a manufacturing agreement with PCAS for ABX464, thus ensuring drug candidate supply for upcoming clinical trials April 25, 2016 Read More ABIVAX obtains regulatory and ethics clearance in Spain to begin second Phase IIa clinical trial for ABX464 in HIV/AIDS patients April 19, 2016 Read More ABIVAX to participate in the European Small-Cap Event in Paris on April 11-12, 2016 March 31, 2016 Read More ABIVAX - 2015 Full-Year Results and Progress Report March 15, 2016 Read More ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa February 25, 2016 Read More ABIVAX to participate in the upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London February 11, 2016 Read More
ABIVAX completes the second milestone in CaReNa, a “Strategic Industrial Innovation Project” supported by Bpifrance September 13, 2016 Read More
Analysis of ongoing ABX203 Phase IIb/III trial in chronic hepatitis B virus infection shows good safety, but primary endpoint of study is unlikely to be reached June 17, 2016 Read More
ABIVAX launches ABX464-004 study; First patient enrolled in second Phase IIa trial May 30, 2016 Read More
ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa April 27, 2016 Read More
ABIVAX enters into a manufacturing agreement with PCAS for ABX464, thus ensuring drug candidate supply for upcoming clinical trials April 25, 2016 Read More
ABIVAX obtains regulatory and ethics clearance in Spain to begin second Phase IIa clinical trial for ABX464 in HIV/AIDS patients April 19, 2016 Read More
ABIVAX to participate in the European Small-Cap Event in Paris on April 11-12, 2016 March 31, 2016 Read More
ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa February 25, 2016 Read More
ABIVAX to participate in the upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London February 11, 2016 Read More
